Patent ID: 7820375

Claim:
A method for in vitro screening for a pathology involving a dysfunction of the T lymphocytes, said method comprising: a) evaluating the level of expression, the location, or the phosphorylation of a Collapsin Response Mediator Protein (CRMP) in cells of the immune system taken from a patient; and b) comparing the level of expression, location or the phosphorylation of said CRMP with the level of expression, location or the phosphorylation of said Collapsin Response Mediator Proteins in control cells of the immune system from a healthy subject, wherein an increased expression, or modified location, or modified phosphorylation of said CRMP in the cells of the immune system taken from said patient as compared to the expression, the location or the phosphorylation of said CRMP in the control cells of the immune system obtained from said healthy subject is indicative of a pathology involving a dysfunction of the T lymphocytes, wherein the Collapsin Response Mediator Protein is CRMP2 or CRMP5, and wherein said pathology is selected from the group consisting of: T leukaemias and lymphomas, viral infections, wherein the viral infection is selected from the group consisting of measles virus and HTLV-1; and multiple sclerosis.